Kidney Fibrosis Articles & Analysis
7 news found
To further streamline our portfolio, we have decided to discontinue activities in fibrosis and kidney disease to allow for increased investments in our oncology franchise. ...
“Our new fit-for-purpose organizational structure and operating model will focus on accelerating our pipeline in immunology and oncology, supported by externally sourced opportunities, and we will discontinue our activities in fibrosis and kidney disease2. As a result of our new strategic direction, we intend to reduce our workforce by approximately 200 ...
“Their cumulative experience with public and private biotech companies will be of great value to us as we advance our vision of serving patients suffering from Diabetic Kidney Diseases and Fibrosis with our new class of CB1 inverse agonists”, added Dr. ...
The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). The collaboration has already achieved two major milestones, with the first novel targets added to ...
The ExoTRU test will be the first ever commercially available test capable of discriminating between types of kidney rejection, providing critical information to assist clinician decision making and optimize patient care. ...
Kidney fibrosis (KF) is a pathological hallmark of CKD and a major contributing factor to progression to end-stage CKD. Developing an effective therapy that targets kidney fibrosis would be a significant leap forward with the potential to greatly improve patient outcomes, slowing or even halting CKD progression. ...
LTI-03 has demonstrated anti-fibrotic activity in multiple models of fibrosis, including scleroderma, kidney and cardiac, as well as the ability to protect healthy lung cells in pre-clinical testing. ...